GC-207

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameGC-207

Drug Alias Nameallogeneic CAR T-cell therapy (Gracell Biotechnologies)GC-207

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunostimulantsT lymphocytes stimulants

TargetsUpdating

Therapy Area/IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaPending

Originator CompaniesGracell Biotechnologies Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGracell Biotechnologies Inc

Active IndicationsN/A

Inactive IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A